Seaport Therapeutics and Hemab Therapeutics moved toward public markets as the biotech IPO window shows signs of reopening, each filing for IPO plans to fund clinical and pipeline work. Seaport is preparing for an initial public offering and said it intends to use proceeds primarily for a Phase 2b study of SPT-300 (brexanolone caprilcerbate) in major depressive disorder, with topline timing aimed for next year and plans to advance into Phase 3. The company also outlined additional development for other depression and sleep-related candidates. Hemab, which is also positioning for an IPO, is focused on therapies for clotting disorders. Together, the filings highlight how capital markets activity is accelerating for late-stage-preclinical development strategies tied to near-term readouts.